Literature DB >> 11286481

Frequent k- ras -2 mutations and p16(INK4A)methylation in hepatocellular carcinomas in workers exposed to vinyl chloride.

M Weihrauch1, M Benicke, G Lehnert, C Wittekind, R Wrbitzky, A Tannapfel.   

Abstract

Vinyl chloride (VC) is a know animal and human carcinogen associated with liver angiosarcomas (LAS) and hepatocellular carcinomas (HCC). In VC-associated LAS mutations of the K- ras -2 gene have been reported; however, no data about the prevalence of such mutations in VC associated HCCs are available. Recent data indicate K- ras -2 mutations induce P16 methylation accompanied by inactivation of the p16 gene. The presence of K- ras -2 mutations was analysed in tissue from 18 patients with VC associated HCCs. As a control group, 20 patients with hepatocellular carcinoma due to hepatitis B (n = 7), hepatitis C (n = 5) and alcoholic liver cirrhosis (n = 8) was used. The specific mutations were determined by direct sequencing of codon 12 and 13 of the K- ras -2 gene in carcinomatous and adjacent non-neoplastic liver tissue after microdissection. The status of p16 was evaluated by methylation-specific PCR (MSP), microsatellite analysis, DNA sequencing and immunohistochemical staining. All patients had a documented chronic quantitated exposure to VC (average 8883 ppmy, average duration: 245 months). K- ras -2 mutations were found in 6 of 18 (33%) examined VC-associated HCCs and in 3 cases of adjacent non-neoplastic liver tissue. There were 3 G --> A point mutations in the tumour tissue. All 3 mutations found in non-neoplastic liver from VC-exposed patients were also G --> A point mutations (codon 12- and codon 13-aspartate mutations). Hypermethylation of the 5' CpG island of the p16 gene was found in 13 of 18 examined carcinomas (72%). Of 6 cancers with K- ras -2 mutations, 5 specimens also showed methylated p16. Within the control group, K- ras -2 mutation were found in 3 of 20 (15%) examined HCC. p16 methylation occurred in 11 out of 20 (55%) patients. K- ras -2 mutations and p16 methylation are frequent events in VC associated HCCs. We observed a K- ras -2 mutation pattern characteristic of chloroethylene oxide, a carcinogenic metabolite of VC. Our results strongly suggest that K- ras -2 mutations play an important role in the pathogenesis of VC-associated HCC. Copyright 2001 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11286481      PMCID: PMC2363841          DOI: 10.1054/bjoc.2000.1675

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  42 in total

1.  Aberrant methylation of p16INK4a and deletion of p15INK4b are frequent events in human esophageal cancer in Linxian, China.

Authors:  E P Xing; Y Nie; L D Wang; G Y Yang; C S Yang
Journal:  Carcinogenesis       Date:  1999-01       Impact factor: 4.944

2.  Expression of p73 and its relation to histopathology and prognosis in hepatocellular carcinoma.

Authors:  A Tannapfel; M Wasner; K Krause; F Geissler; A Katalinic; J Hauss; J Mössner; K Engeland; C Wittekind
Journal:  J Natl Cancer Inst       Date:  1999-07-07       Impact factor: 13.506

3.  p16(INK4a) and the control of cellular proliferative life span.

Authors:  L I Huschtscha; R R Reddel
Journal:  Carcinogenesis       Date:  1999-06       Impact factor: 4.944

4.  Metabolic activation of vinyl chloride by rat liver microsomes: low-dose kinetics and involvement of cytochrome P450 2E1.

Authors:  F el Ghissassi; A Barbin; H Bartsch
Journal:  Biochem Pharmacol       Date:  1998-05-01       Impact factor: 5.858

5.  A new member of the endonuclease III family of DNA repair enzymes that removes methylated purines from DNA.

Authors:  T J Begley; B J Haas; J Noel; A Shekhtman; W A Williams; R P Cunningham
Journal:  Curr Biol       Date:  1999-06-17       Impact factor: 10.834

6.  Critical genes as early warning signs: example of vinyl chloride.

Authors:  M J Marion
Journal:  Toxicol Lett       Date:  1998-12-28       Impact factor: 4.372

Review 7.  Mutation spectra resulting from carcinogenic exposure: from model systems to cancer-related genes.

Authors:  E Dogliotti; P Hainaut; T Hernandez; M D'Errico; D M DeMarini
Journal:  Recent Results Cancer Res       Date:  1998

8.  High frequency of p16INK4A gene alterations in hepatocellular carcinoma.

Authors:  C T Liew; H M Li; K W Lo; C K Leow; J Y Chan; L Y Hin; W Y Lau; P B Lai; B K Lim; J Huang; W T Leung; S Wu; J C Lee
Journal:  Oncogene       Date:  1999-01-21       Impact factor: 9.867

9.  Increased morbidity odds ratio of primary liver cancer and cirrhosis of the liver among vinyl chloride monomer workers.

Authors:  C L Du; J D Wang
Journal:  Occup Environ Med       Date:  1998-08       Impact factor: 4.402

10.  Plasma Asp13-Ki-ras oncoprotein expression in vinyl chloride monomer workers in Taiwan.

Authors:  J C Luo; H T Liu; T J Cheng; C L Du; J D Wang
Journal:  J Occup Environ Med       Date:  1998-12       Impact factor: 2.162

View more
  15 in total

1.  Interactions of chemical carcinogens and genetic variation in hepatocellular carcinoma.

Authors:  Yu-Jing Zhang
Journal:  World J Hepatol       Date:  2010-03-27

Review 2.  Genetics of hepatocellular carcinoma.

Authors:  Andreas Teufel; Frank Staib; Stephan Kanzler; Arndt Weinmann; Henning Schulze-Bergkamen; Peter-R Galle
Journal:  World J Gastroenterol       Date:  2007-04-28       Impact factor: 5.742

3.  Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma.

Authors:  Michael R O'Dell; Jing Li Huang; Christa L Whitney-Miller; Vikram Deshpande; Paul Rothberg; Valerie Grose; Randall M Rossi; Andrew X Zhu; Hartmut Land; Nabeel Bardeesy; Aram F Hezel
Journal:  Cancer Res       Date:  2012-01-20       Impact factor: 12.701

Review 4.  Hepatocellular carcinoma and the risk of occupational exposure.

Authors:  Venerando Rapisarda; Carla Loreto; Michele Malaguarnera; Annalisa Ardiri; Maria Proiti; Giuseppe Rigano; Evelise Frazzetto; Maria Irene Ruggeri; Giulia Malaguarnera; Nicoletta Bertino; Mariano Malaguarnera; Vito Emanuele Catania; Isidoro Di Carlo; Adriana Toro; Emanuele Bertino; Dario Mangano; Gaetano Bertino
Journal:  World J Hepatol       Date:  2016-05-08

Review 5.  Epigenetic alterations induced by genotoxic occupational and environmental human chemical carcinogens: A systematic literature review.

Authors:  Grace Chappell; Igor P Pogribny; Kathryn Z Guyton; Ivan Rusyn
Journal:  Mutat Res Rev Mutat Res       Date:  2016-03-31       Impact factor: 5.657

6.  Alteration of p53 and p21 during hepatocarcinogenesis in tree shrews.

Authors:  Jian-Jia Su; Ke-Chen Ban; Yuan Li; Liu-Liang Qin; Hui-Yun Wang; Chun Yang; Chao Ou; Xiao-Xian Duan; Young-Lk Lee; Rui-Qi Yang
Journal:  World J Gastroenterol       Date:  2004-12-15       Impact factor: 5.742

7.  Adenoviral gene therapy in hepatocellular carcinoma: a review.

Authors:  Iván Lyra-González; Laura Esther Flores-Fong; Ignacio González-García; David Medina-Preciado; Juan Armendáriz-Borunda
Journal:  Hepatol Int       Date:  2012-04-25       Impact factor: 6.047

Review 8.  Molecular mechanism underlying the functional loss of cyclindependent kinase inhibitors p16 and p27 in hepatocellular carcinoma.

Authors:  Yasunobu Matsuda
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

9.  Prevalence of K-Ras mutations in hepatocellular carcinoma: A Turkish Oncology Group pilot study.

Authors:  Nazim Serdar Turhal; Berna Savaş; Öznur Çoşkun; Emine Baş; Bülent Karabulut; Deniz Nart; Taner Korkmaz; Dilek Yavuzer; Gökhan Demir; Gülen Doğusoy; Mehmet Artaç
Journal:  Mol Clin Oncol       Date:  2015-08-31

10.  Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma.

Authors:  Cécile Guichard; Giuliana Amaddeo; Sandrine Imbeaud; Yannick Ladeiro; Laura Pelletier; Ichrafe Ben Maad; Julien Calderaro; Paulette Bioulac-Sage; Mélanie Letexier; Françoise Degos; Bruno Clément; Charles Balabaud; Eric Chevet; Alexis Laurent; Gabrielle Couchy; Eric Letouzé; Fabien Calvo; Jessica Zucman-Rossi
Journal:  Nat Genet       Date:  2012-05-06       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.